Han Changxu, Liu Ming, Lian Xin, Sun Tao, Yan Shengjuan, Bai Xianming, Gan Dige, Leng Bing, Qiu Yi, Ren Yizhong
Sports Medicine Center, The Second Affiliated Hospital of Inner Mongolia Medical University, Hohhot, Inner Mongolia, China.
Emergency Center, The Second Affiliated Hospital of Inner Mongolia Medical University, Hohhot, Inner Mongolia, China.
J Shoulder Elbow Surg. 2023 Nov;32(11):2389-2399. doi: 10.1016/j.jse.2023.06.013. Epub 2023 Jul 17.
Although tranexamic acid (TXA) is being increasingly used in orthopedic arthroplasty and lower-extremity arthroscopic procedures, its use in arthroscopic rotator cuff repair (ARCR) is less widely reported. The aim of this study was to evaluate the clinical effectiveness and safety of TXA administration in ARCR.
A systematic review and meta-analysis of randomized controlled trials was performed to compare clinical outcomes in patients who underwent ARCR with or without TXA. Literature was retrieved using the Cochrane Library, MEDLINE, PubMed, and Embase electronic databases. The primary outcome of this study was visual clarity. Secondary outcomes contained total operative time, postoperative pain score, amount of blood loss, shoulder swelling (change in shoulder circumference), volume of irrigation fluid, number of adjustments of the pump pressure for irrigation, and adverse cardiovascular events.
Seven studies (3 and 4 with level I and II evidence, respectively), which included 272 and 265 patients who underwent arthroscopy with and without TXA, respectively, met the eligibility criteria. Pooled analysis showed significant improvements in visual clarity (mean difference, 9.10%; 95% CI, 4.05-14.15; P = .0004) and total operative time (mean difference, -11.24 minute; 95% CI, -19.90 to -2.57) associated with perioperative TXA application. None of the trials reported adverse events and complications associated with TXA.
The best available evidence indicates that TXA administration could significantly improve arthroscopic visual clarity and effectively save operative time in ARCR without increasing the incidence of adverse events. Furthermore, the optimal dose, route, and timing of TXA application in ARCR surgery remains to be validated by future high-level evidence studies.
尽管氨甲环酸(TXA)在骨科关节置换术和下肢关节镜手术中的应用越来越广泛,但其在关节镜下肩袖修复术(ARCR)中的应用报道较少。本研究的目的是评估TXA在ARCR中的临床有效性和安全性。
进行了一项随机对照试验的系统评价和荟萃分析,以比较接受或未接受TXA的ARCR患者的临床结局。使用Cochrane图书馆、MEDLINE、PubMed和Embase电子数据库检索文献。本研究的主要结局是视野清晰度。次要结局包括总手术时间、术后疼痛评分、失血量、肩部肿胀(肩围变化)、冲洗液量、冲洗泵压力调整次数和不良心血管事件。
七项研究(分别有3项和4项具有I级和II级证据)符合纳入标准,其中分别有272例和265例患者接受了使用和未使用TXA的关节镜检查。汇总分析显示,围手术期应用TXA可显著改善视野清晰度(平均差异,9.10%;95%CI,4.05-14.15;P = .0004)和总手术时间(平均差异,-11.24分钟;95%CI,-19.90至-2.57)。没有试验报告与TXA相关的不良事件和并发症。
现有最佳证据表明,TXA给药可显著提高ARCR的关节镜视野清晰度并有效节省手术时间,且不增加不良事件的发生率。此外,ARCR手术中TXA应用的最佳剂量、途径和时机仍有待未来的高级别证据研究验证。